EML4 and non-small cell lung carcinoma: To characterize the novel F1174S mutation in the context of ALK-positive NSCLC, we introduced it into EML4-ALK V1, EML4-ALK V3a and EML4-ALK V3b constructs, hereafter referred to as EML4-ALK (F1174S) V1, EML4-ALK (F1174S) V3a and EML4-ALK (F1174S) V3b.